Catalytic activity of three variants (Ile, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single-strand conformation polymorphism analysis

被引:64
作者
Ieiri, I
Tainaka, H
Morita, T
Hadama, A
Mamiya, K
Hayashibara, M
Ninomiya, H
Ohmori, S
Kitada, M
Tashiro, N
Higuchi, S
Otsubo, K
机构
[1] Tottori Univ, Fac Med, Dept Hosp Pharm, Yonago, Tottori 6838504, Japan
[2] Asahi Techno Glass Corp, Life Sci Lab, Funabashi, Chiba, Japan
[3] Kyushu Univ, Fac Med, Dept Neuropsychiat, Fukuoka 812, Japan
[4] Chiba Univ Hosp, Div Pharm, Chiba, Japan
[5] Kyushu Univ, Fac Med, Dept Pharmaceut Sci, Fukuoka 812, Japan
关键词
CYP2C9; new variant; catalytic activity; single-strand conformation polymorphism (SSCP) analysis;
D O I
10.1097/00007691-200006000-00001
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
This study evaluated the catalytic activity of three variants (Ile, Leu, and Thr) at codon 359 of CYP2C9 enzymes expressed in a yeast cDNA expression system, and then established single-strand conformation polymorphism (PCR-SSCP) analysis for simultaneous detection as a screening method. Diclofenac was used for the in vitro experiment, and its: hydroxy metabolite (4'-hydroxydiclofenac) was measured by HPLC. To discuss the in vivo effect of the Thr359 variant on the pharmacokinetics of phenytoin, a case report is presented. The efficiency of the SSCP method was evaluated by analyzing DNA samples from a homozygote fur Ile359 and a heterozygote for Leu359 or Thr359, To evaluate the interaction between the P450 level and reductase activity, two batches of the Thr359 variant with a different P450:reductase activity ratio (1:4.0 and 1:1.4) were used, The in vitro study revealed that recombinant Ile359, Leu359, and Thr359 (2 batches) possessed a mean K-m of 2.0, 16.5 and (3.8 and 2.9) mu mol and V-max of 12.4, 17.9 and (4.4 and 5.1) nmol/min/nmol P450, respectively. Although the magnitude of the change in catalytic efficiency for the Thr359 variant was close to that of the Leu359 variant, the effect of the two variants on diclofenac 4'-hydroxylation appears to be different because Leu359 variant was associated with a high K-m, and Thr359 with a low V-max. No significant differences in the kinetic data were observed between the two Thr359 enzymes, suggesting that low reductase activity in the Thr359 enzyme was not a major determinant in the present in vitro experiment. Estimated pharmacokinetic parameters of phenytoin obtained by the Bayesian method in an epileptic patient who was a heterozygote carrier for Thr359 variant were: K-m = 6.45 mu g/mL, V-max = 5.77 mg/kg/d, and V-max/K-m = 0.89 L/kg/ay. The V-max/K-m value in this patient was similar to the population mean value (0.90 L/kg/day) in Japanese heterozygotes for the Leu359 variant. Results for PCR-SSCP were in complete agreement with those obtained using established methods, Thus, the PCR-SSCP approach is useful for identifying these three variants of the CYP2C9 gene.
引用
收藏
页码:237 / 244
页数:8
相关论文
共 34 条
[1]   Allelic and functional variability of cytochrome P4502C9 [J].
Bhasker, CR ;
Miners, JO ;
Coulter, S ;
Birkett, DJ .
PHARMACOGENETICS, 1997, 7 (01) :51-58
[2]   An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis [J].
Broly, F ;
Marez, D ;
Sabbagh, N ;
Legrand, M ;
Millecamps, S ;
LoGuidice, JM ;
Boone, P ;
Meyer, UA .
PHARMACOGENETICS, 1995, 5 (06) :373-384
[3]   The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase [J].
Crespi, CL ;
Miller, VP .
PHARMACOGENETICS, 1997, 7 (03) :203-210
[4]   HIGH-LEVEL EXPRESSION OF HUMAN LIPOCORTIN-I IN THE FISSION YEAST SCHIZOSACCHAROMYCES-POMBE USING A NOVEL EXPRESSION VECTOR [J].
GIGAHAMA, Y ;
TOHDA, H ;
OKADA, H ;
OWADA, MK ;
OKAYAMA, H ;
KUMAGAI, H .
BIO-TECHNOLOGY, 1994, 12 (04) :400-404
[5]   BIOCHEMISTRY AND MOLECULAR-BIOLOGY OF THE HUMAN CYP2C SUBFAMILY [J].
GOLDSTEIN, JA ;
DEMORAIS, SMF .
PHARMACOGENETICS, 1994, 4 (06) :285-299
[6]   PHARMACOGENETIC PHENOTYPING AND GENOTYPING - PRESENT STATUS AND FUTURE POTENTIAL [J].
GONZALEZ, FJ ;
IDLE, JR .
CLINICAL PHARMACOKINETICS, 1994, 26 (01) :59-70
[7]  
GOTOH O, 1992, J BIOL CHEM, V267, P83
[8]   Allelic variants of human cytochrome P450 2C9: Baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms [J].
Haining, RL ;
Hunter, AP ;
Veronese, ME ;
Trager, WF ;
Rettie, AE .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1996, 333 (02) :447-458
[9]  
Hayashi K, 1991, PCR Methods Appl, V1, P34
[10]   Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients:: genetic analysis of the CYP2C9 locus [J].
Imai, J ;
Ieiri, I ;
Mamiya, K ;
Miyahara, S ;
Furuumi, H ;
Nanba, E ;
Yamane, M ;
Fukumaki, Y ;
Ninomiya, H ;
Tashiro, N ;
Otsubo, K ;
Higuchi, S .
PHARMACOGENETICS, 2000, 10 (01) :85-89